1. OCS-01 targets diabetic macular edema (DME) via topical delivery.
2. It utilizes OPTIREACH technology for enhanced efficacy.
3. Existing DME treatments often lead to low patient compliance.
4. OCS-05 aims to treat acute optic neuritis with neuroprotective benefits.
5. Recent trials show significant improvements in visual acuity and retinal health with OCS-05.
6. The importance of early treatment in DME for better patient outcomes is underscored.
7. Plans for FDA meetings for potential registration of OCS-05 are underway.
